Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Price Performance

Evogene stock opened at $1.29 on Friday. Evogene has a one year low of $1.20 and a one year high of $10.40. The business’s fifty day moving average is $1.88 and its 200 day moving average is $3.68. The stock has a market capitalization of $6.92 million, a PE ratio of -0.29 and a beta of 1.36.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.